HPN424

February 7, 2019

HPN424 Shows Promising Safety, Immune Activation in Metastatic CRPC

News

Preliminary data from an ongoing Phase 1 trial suggest that Harpoon Therapeutics’ investigational therapy HPN424 is safe and effectively activates the immune system in metastatic castration resistant prostate cancer (mCRPC) patients. ... Read more

January 2, 2019

First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424

News

A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer (mCRPC), has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC (Tri-specific T cell Activating Construct) platform. ... Read more